Similar articles for PMID: 11873109

Year	Number of Results
1998	2
1999	5
2000	7
2001	4
2002	5
2003	4
2004	2
2005	5
2006	4
2007	9
2008	4
2009	3
2010	5
2011	4
2012	1
2013	8
2014	6
2015	6
2016	6
2017	16
2018	8
2019	3
2022	1
2024	0

1

Hepatic Fas protein expression might be a predictive factor for hepatocellular carcinoma development in patients with chronic hepatitis C undergoing interferon therapy.

Hirashima N, Matsumoto Y, Ohono T, Kimura Y, Hasegawa I, Ueda R. Hirashima N, et al. J Clin Gastroenterol. 2002 Mar;34(3):263-7. doi: 10.1097/00004836-200203000-00014. J Clin Gastroenterol. 2002. PMID: 11873109

2

Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.

Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, Kumada T, Namisaki T, Yoshiji H, Sakamoto N, Nakagawa M, Asahina Y, Kurosaki M, Izumi N, Enomoto N, Kusakabe A, Kajiwara E, Itoh Y, Ide T, Tamori A, Matsubara M, Kawada N, Shirabe K, Tomita E, Honda M, Kaneko S, Nishina S, Suetsugu A, Hiasa Y, Watanabe H, Genda T, Sakaida I, Nishiguchi S, Takaguchi K, Tanaka E, Sugihara J, Shimada M, Kondo Y, Kawai Y, Kojima K, Nagasaki M, Tokunaga K, Tanaka Y; Japanese Genome-Wide Association Study Group for Viral Hepatitis. Matsuura K, et al. Gastroenterology. 2017 May;152(6):1383-1394. doi: 10.1053/j.gastro.2017.01.041. Epub 2017 Feb 3. Gastroenterology. 2017. PMID: 28163062 Free article.

3

Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.

Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y. Okanoue T, et al. Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S89-91. doi: 10.1016/s1542-3565(05)00701-9. Clin Gastroenterol Hepatol. 2005. PMID: 16234069

4

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy.

Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. Nagaoki Y, et al. J Gastroenterol. 2011 Jun;46(6):799-808. doi: 10.1007/s00535-011-0384-z. Epub 2011 Mar 4. J Gastroenterol. 2011. PMID: 21373851

5

Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.

Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, Butt ZA, Samji H, Cook D, Yu A, Alvarez M, Tyndall M, Krajden M. Janjua NZ, et al. J Hepatol. 2017 Mar;66(3):504-513. doi: 10.1016/j.jhep.2016.10.028. Epub 2016 Nov 4. J Hepatol. 2017. PMID: 27818234

6

Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, Shiga J, Takikawa H. Tanaka A, et al. World J Gastroenterol. 2007 Oct 21;13(39):5180-7. doi: 10.3748/wjg.v13.i39.5180. World J Gastroenterol. 2007. PMID: 17876888 Free PMC article.

7

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H. Arase Y, et al. J Med Virol. 2007 Oct;79(10):1485-90. doi: 10.1002/jmv.20925. J Med Virol. 2007. PMID: 17705189 Clinical Trial.

8

Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up.

Suzuki S, Kondo Y, Hirashima N, Kato H, Sugauchi F, Tanaka Y, Orito E, Yang Y, Shen Y, Sakakibara K, Ueda R, Mizokami M. Suzuki S, et al. J Gastroenterol Hepatol. 2003 Dec;18(12):1364-72. doi: 10.1046/j.1440-1746.2003.03222.x. J Gastroenterol Hepatol. 2003. PMID: 14675264

9

Association between Toll-Like Receptor 3 (TLR3) rs3775290, TLR7 rs179008, TLR9 rs352140 and Chronic HCV.

Mosaad YM, Metwally SS, Farag RE, Lotfy ZF, AbdelTwab HE. Mosaad YM, et al. Immunol Invest. 2019 Apr;48(3):321-332. doi: 10.1080/08820139.2018.1527851. Epub 2018 Oct 15. Immunol Invest. 2019. PMID: 30321082

10

Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.

Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. Veldt BJ, et al. Scand J Gastroenterol. 2006 Sep;41(9):1087-94. doi: 10.1080/00365520600641365. Scand J Gastroenterol. 2006. PMID: 16938723

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

104 results

Results by year